Braeburn to Present Research at CPDD 2026 Annual Meeting, Including Data on Withdrawal Suppression and Real-World Treatment Retention in Patients With Opioid Use Disorder

Braeburn today announced it will present two oral presentations and two posters at the 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD), taking place June 13–17, ...
Healthline

All About Brixadi

Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...
ksn.com

BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...
KOIN 6

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...